- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05182957
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
January 28, 2023 updated by: The First Affiliated Hospital of Soochow University
Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Peripheral T-cell lymphomas (PTCLs) are malignancies of immunologically mature T-cells that arise in peripheral lymphoid tissues.
Compared with B-cell lymphoma, the treatment methods of PTCL are more limited, the first-line therapy is usually CHOP-like therapy, but the efficacy is poor, 5-year overall survival rate (OS) is only 30%-40%.
Anti-PD-1 monoclonal antibody, Lenalidomide and Azacitidine can all have tumor-killing effects, and the three have complementary theoretical basis in the mechanism of action.
This study will evaluate the efficacy and safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma patients.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- The First Affiliated Hospital of Soochow University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathological immunohistochemistry or flow cytometry confirmed that R/R PTCL with measurable (diameter greater than 1.5cm) lesions meets any of the following conditions: 1> After 4 courses of standard first-line therapy or 2 courses of more than two-line therapy, the lesions were reduced by <50%; 2> PTCL with disease progression after first-line or induction therapy; 3> After hematopoietic stem cell transplantation, new lesions appear or the size of previously affected lesions increased by more than 50%.
- Age ≥ 18 years.
- ECOG≤2分.
- The main organ functions need to meet the following conditions:Hemogram needs to meet HB ≥70*1012/L,PLT≥50*109/L,NE≥1*109/L;LVEF≥50%;CR≤132umol/l or CCr≥60 ml/min;ALT and AST≤2 times normal range;Lung function≤Level 1;dyspnea(CTCAE v5.0),and blood oxygen saturation without oxygen absorption> 91%.
- Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up one year period of the study.
- Estimated survival time ≥3 months.
- Voluntary signing of informed consent.
Exclusion Criteria:
- Accepted major surgery within 4 weeks before treatment.
- Prior malignancy (other than Relapsed/Refractory Peripheral T-cell Lymphoma), except for cured malignant tumors with no active lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer,malignant tonsilloma or carcinoma in situ;
- Patients who have previously received failed allogeneic hematopoietic stem cell transplantation.
- Have stroke or intracranial hemorrhage within 3 months.
- Evidence of complications or medical conditions, including but not limited, that may interfere the conduct of the study or place the patient at serious risk:significant cardiovascular disease(class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification、myocardial infarction within 6 months of screening、uncontrolled or symptomatic arrhythmias) and/or significant lung disease.
- HIV infection and/or active hepatitis B or active hepatitis C.
- Uncontrolled systemic infection.
- Pregnant or breasting-feeding women.
- According to the researchers' judgment, any life-threatening disease, medical condition or organ system dysfunction which can endanger the patient's safety and Interfer with the absorption or metabolism of anti-PD-1 monoclonal antibody plus Lenalidomide and Azacitidine,may put the results of a study at unnecessary risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Anti-PD-1 monoclonal antibody+Lenalidomide+Azacitidine
Anti-PD-1 monoclonal antibody plus Lenalidomide, Azacitidine
|
Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
Other Names:
Lenalidomide 25mg qd po d1-d10 (/21d)
Other Names:
Azacitidine 75mg/m2 i.v d1-d7 (/21d)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival(PFS)
Time Frame: up to 12 months
|
To measure the duration of response to Anti-PD-1 antibody plus Lenalidomide and Azacitidine over a follow-up period of 12 months
|
up to 12 months
|
Overall Response Rate (ORR)
Time Frame: up to 12 months
|
To measure the duration of response to Anti-PD-1 antibody plus Lenalidomide and Azacitidine over a follow-up period of 12 months
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events profile
Time Frame: Measured from start of treatment until 28 days after last dose
|
Number of participants with adverse events.
Frequencies of toxicities based on the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 will be tabulated
|
Measured from start of treatment until 28 days after last dose
|
Complete Response Rate
Time Frame: up to 12 months
|
Number of patients who achieved complete response after treatment by Anti-PD-1 antibody plus Lenalidomide and Azacitidine
|
up to 12 months
|
Duration of Response
Time Frame: up to 12 months
|
Duration of overall response will be assessed from the first Anti-PD-1 antibody plus Lenalidomide and Azacitidine given to progression,death or last follow-up.
|
up to 12 months
|
Overall Survival
Time Frame: up to 12 months
|
OS will be assessed from the first Anti-PD-1 antibody plus Lenalidomide and Azacitidine given to death or last follow-up.
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 14, 2022
Primary Completion (ANTICIPATED)
December 14, 2023
Study Completion (ANTICIPATED)
December 14, 2023
Study Registration Dates
First Submitted
December 16, 2021
First Submitted That Met QC Criteria
December 21, 2021
First Posted (ACTUAL)
January 10, 2022
Study Record Updates
Last Update Posted (ACTUAL)
January 31, 2023
Last Update Submitted That Met QC Criteria
January 28, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibodies
- Lenalidomide
- Immunoglobulins
- Azacitidine
- Immunologic Factors
- Antibodies, Monoclonal
Other Study ID Numbers
- R/R PTCL 01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Peripheral T-cell Lymphoma
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
Sun Yat-sen UniversityNot yet recruitingRelapsed and Refractory Peripheral T-cell LymphomaChina
-
Mundipharma (China) Pharmaceutical Co. LtdCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed T-Cell LymphomaChina
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory Peripheral T-cell LymphomaChina
-
Dizal PharmaceuticalsCompletedRelapsed or Refractory Peripheral T Cell LymphomaKorea, Republic of, United States, China, Australia
Clinical Trials on Anti-PD-1 monoclonal antibody
-
Henlix, IncUnknown
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
Guangzhou Gloria Biosciences Co., Ltd.CompletedAdvanced Solid TumorsChina
-
Genor Biopharma Co., Ltd.RecruitingAlveolar Soft Part SarcomaChina
-
Shanghai Henlius BiotechRecruiting
-
Genor Biopharma Co., Ltd.RecruitingPeripheral T Cell LymphomaChina
-
RenJi HospitalCompletedNeoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial CarcinomaChina